Spinal Cord Injury Research Program Advanced Technology Therapeutic Development Award | Apply Online

Opportunity Summary:

The Spinal Cord Injury Research Program (SCIRP) Advanced Technology/Therapeutic Development Award (AT/TDA) is a Department of Defense funding opportunity designed to push promising spinal cord injury (SCI) treatments and technologies closer to real-world clinical use. It focuses on product-driven work rather than early discovery science, supporting studies that demonstrate and refine pharmaceuticals (including drugs, biologics, and vaccines) and medical devices in either robust preclinical settings and/or clinical research settings. The central purpose is to evaluate therapeutics and devices that can treat, prevent, detect, or diagnose SCI, with an emphasis on generating the kind of practical evidence needed to move a candidate intervention along the development pipeline and toward patient impact.

A key feature of this mechanism is its “translation-forward” mindset: projects should be empirical, clearly aimed at advancing a specific product or technology, and generally expected to be at or beyond Biomedical Technology Readiness Level (TRL) 4. In practical terms, that means applicants should not be proposing exploratory concepts with minimal validation. Instead, the program is looking for interventions that already have credible supporting evidence and are ready for structured demonstration, refinement, and de-risking steps that would make them viable for later-stage testing or deployment. The award can support several types of activities that help close the gap between laboratory progress and clinical adoption, including cognitive or behavioral clinical studies, clinical intervention studies that do not rise to the level of a regulatory clinical trial, and targeted preclinical work aimed at enabling the next regulatory steps.

The preclinical component the program highlights is especially oriented toward data packages that regulators and developers typically need before launching formal clinical trials. Examples include Good Laboratory Practice (GLP) animal safety and toxicity studies, identifying efficacy endpoints (or well-justified surrogate endpoints) in relevant animal models, and collecting sufficient supporting data to underpin an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) application. Put simply, the award is meant to fund the kind of rigorous, decision-making evidence that either justifies moving into clinical trials after the award or clarifies what still needs to be addressed before a product is ready.

At the same time, there are clear boundaries on what the award will not support. It is not intended for fundamental basic research, and it cannot be used to run clinical trials intended to support regulatory submissions for new or expanded indications, described in the announcement as Phase I through Phase IV clinical trials. Human studies are allowed, but applicants must stay within the definition of clinical research that is not a regulated clinical trial for the purposes described above. The announcement points applicants to additional guidance (Appendix 6 in the general application instructions) to help distinguish clinical trials from other forms of clinical research, and it notes that investigators specifically seeking support for a clinical trial should consider the separate SCIRP Clinical Trial Award/Rehabilitation mechanism.

Military relevance is not optional in this opportunity; it is a required and central evaluation element. Every application must clearly explain why the proposed SCI technology or therapeutic matters to the military context, and how it connects to service member or veteran needs. Because of that, the program strongly encourages applicants to collaborate with and integrate their work with Department of Defense and/or Department of Veterans Affairs (VA) laboratories and programs. The announcement even lists multiple DOD and related research organizations and information resources (for example, CDMRP, DTIC, USAMRMC, DARPA, service research labs, and VA R&D) as potential starting points for alignment and partnership.

Another defining requirement is the expectation for a credible transition plan. Each principal investigator must lay out how the product will move forward after the award, including what funding and resources will be used to progress to clinical trials and/or to deliver the product to the military market if the work is successful. This makes the AT/TDA fundamentally different from grants that end with a publication; reviewers are looking for practical development steps, ownership of next actions, and evidence that the team understands the path to adoption, whether that is through regulatory submission preparation, manufacturing/scale considerations, clinical readiness, or a clear partner pathway.

The opportunity also includes a structured “Partnering PI” option meant to promote true scientific collaboration rather than loose subcontracting. Under this option, up to three PIs can jointly lead a single integrated project: one Initiating PI manages most submission-related administration, and up to two Partnering PIs contribute with equal intellectual engagement in shaping the research plan. Separate awards are made to each PI’s institution, and multi-institutional, multidisciplinary projects are explicitly allowed. However, the announcement is clear that token partnerships do not meet the intent; for example, a partner who only provides samples, access to patients, or routine services would not qualify as a genuine Partnering PI arrangement. Teams are also expected to plan for active communication across institutions and to proactively address intellectual property and material transfer issues so they do not become barriers to collaboration or product transition.

For projects involving human subjects or human biological substances, the regulatory expectations are substantial. In addition to local Institutional Review Board (IRB) review, all DOD-funded human subjects research must be reviewed and approved by the USAMRMC Office of Research Protections, Human Research Protection Office (HRPO). The announcement cautions applicants to plan for a minimum of six months for regulatory review and approvals, reflecting the detailed DOD-specific compliance requirements beyond what many institutions are used to handling through local review alone.

From an administrative standpoint, the opportunity was issued by the Department of the Army (USAMRAA) under Funding Opportunity Number W81XWH-09-SCIRP-ATTDA. It was posted July 13, 2009, with a closing date of December 10, 2009, and an estimated total funding amount of $6.72 million with an expectation of about three awards. The funding instrument type is listed as grant and cooperative agreement, there is no cost sharing requirement, eligibility is described as unrestricted (open broadly to entity types unless otherwise clarified in the full text), and it is associated with CFDA 12.420 (Military Medical Research and Development). For support, the announcement provides contacts for general program announcement access issues and the CDMRP eReceipt/help desk for submission-related problems.

Browse more business programs for Technology Service Providers

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Youth Education

Previous opportunity: Psychological Health and Traumatic Brain Injury Research Program Investigator Initiated Research Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 09 SCIRP ATTDA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 09 SCIRP ATTDA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 09 SCIRP ATTDA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.